Stayble Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:STABL Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
06 Dec 24	BuySEK 18,800	Andreas Gerward	Individual		40,000	SEK 0.47

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of STABL?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,881,137	4.48%
VC/PE Firms	5,393,940	8.38%
Institutions	14,153,283	22%
General Public	41,931,432	65.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 102.9%.

Top Shareholders

Top 15 shareholders own 34.85% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.38%	Chalmers Ventures AB	5,393,940	SEK 2.3m	0%	8.71%
5.53%	Avanza Fonder AB	3,559,441	SEK 1.5m	0%	no data
5.21%	Chalmers Tekniska Högskola, Endowment Arm	3,355,940	SEK 1.4m	0%	68.34%
3.01%	Almi Invest AB	1,935,584	SEK 831.3k	0%	3.14%
2.72%	Nordnet AB (publ), Asset Management Arm	1,748,371	SEK 750.9k	0%	0.01%
2.24%	Handelsbanken Asset Management	1,439,494	SEK 618.3k	0%	no data
1.75%	Robert Joki	1,127,804	SEK 484.4k	0%	no data
1.57%	Nordnet Pensionsförsäkring Ab, Asset Management Arm	1,011,449	SEK 434.4k	0%	0.01%
0.93%	Andreas Gerward	600,000	SEK 257.7k	0%	no data
0.92%	Futur Pension Försäkringsaktiebolag, Asset Management Arm	595,000	SEK 255.6k	0%	0.01%
0.8%	Alirami Baftijari	515,333	SEK 221.3k	0%	no data
0.78%	Ålandsbanken Asset Management Ab	505,200	SEK 217.0k	0%	0.04%
0.78%	Kjell Olmarker	500,000	SEK 214.7k	0%	no data
0.21%	Thomas Palsson	138,000	SEK 59.3k	0%	no data
0.0044%	FCG Fonder AB	2,804	SEK 1.2k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/30 03:35
End of Day Share Price	2025/06/30 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stayble Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.